Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Varicose Ulcer | 24 | 2021 | 53 | 6.170 |
Why?
|
Varicose Veins | 22 | 2020 | 148 | 5.920 |
Why?
|
Venous Insufficiency | 19 | 2020 | 110 | 5.560 |
Why?
|
Glycosaminoglycans | 6 | 2020 | 602 | 2.530 |
Why?
|
Vena Cava, Inferior | 10 | 2020 | 437 | 2.470 |
Why?
|
Vasodilation | 9 | 2019 | 957 | 1.980 |
Why?
|
Vasoconstriction | 10 | 2020 | 603 | 1.950 |
Why?
|
Aortic Aneurysm, Abdominal | 13 | 2022 | 1154 | 1.440 |
Why?
|
E-Selectin | 2 | 2022 | 590 | 1.370 |
Why?
|
Saphenous Vein | 4 | 2017 | 512 | 1.320 |
Why?
|
Vasoconstrictor Agents | 10 | 2020 | 628 | 1.290 |
Why?
|
Venous Thrombosis | 6 | 2022 | 1216 | 1.270 |
Why?
|
Matrix Metalloproteinase 2 | 5 | 2020 | 480 | 1.230 |
Why?
|
Femoral Artery | 6 | 2016 | 844 | 1.220 |
Why?
|
Wound Healing | 11 | 2017 | 2778 | 1.210 |
Why?
|
Matrix Metalloproteinases | 7 | 2017 | 402 | 1.180 |
Why?
|
Leg | 5 | 2021 | 1115 | 1.170 |
Why?
|
Blood Vessel Prosthesis Implantation | 10 | 2022 | 1309 | 1.140 |
Why?
|
Veins | 5 | 2017 | 745 | 1.110 |
Why?
|
Leg Ulcer | 2 | 2016 | 70 | 1.100 |
Why?
|
Matrix Metalloproteinase 9 | 3 | 2020 | 685 | 0.980 |
Why?
|
Muscle, Smooth, Vascular | 8 | 2016 | 1571 | 0.920 |
Why?
|
Iliac Vein | 2 | 2020 | 69 | 0.900 |
Why?
|
Fibroblasts | 10 | 2009 | 4233 | 0.870 |
Why?
|
Arterial Occlusive Diseases | 5 | 2016 | 782 | 0.860 |
Why?
|
Aneurysm | 2 | 2017 | 319 | 0.840 |
Why?
|
Endothelium, Vascular | 5 | 2019 | 4586 | 0.760 |
Why?
|
Vascular Diseases | 4 | 2020 | 1141 | 0.750 |
Why?
|
Vascular Surgical Procedures | 10 | 2022 | 1451 | 0.750 |
Why?
|
Nitric Oxide | 5 | 2019 | 2123 | 0.710 |
Why?
|
Stockings, Compression | 4 | 2020 | 38 | 0.700 |
Why?
|
Lower Extremity | 7 | 2019 | 1043 | 0.690 |
Why?
|
Chronic Disease | 22 | 2018 | 9030 | 0.690 |
Why?
|
Endarterectomy, Carotid | 2 | 2022 | 527 | 0.660 |
Why?
|
Leukocytes | 4 | 2017 | 2092 | 0.650 |
Why?
|
Thrombophlebitis | 3 | 2014 | 310 | 0.590 |
Why?
|
Peripheral Vascular Diseases | 4 | 2010 | 551 | 0.590 |
Why?
|
Phenylephrine | 8 | 2016 | 293 | 0.580 |
Why?
|
Endovascular Procedures | 7 | 2022 | 1925 | 0.580 |
Why?
|
Intermittent Claudication | 4 | 2016 | 304 | 0.550 |
Why?
|
Glycocalyx | 1 | 2016 | 80 | 0.540 |
Why?
|
Carotid Stenosis | 1 | 2022 | 812 | 0.540 |
Why?
|
Portal Vein | 1 | 2017 | 425 | 0.530 |
Why?
|
Ultrasonography, Doppler, Duplex | 2 | 2013 | 206 | 0.510 |
Why?
|
Anti-Inflammatory Agents | 2 | 2014 | 1785 | 0.500 |
Why?
|
Anticoagulants | 3 | 2020 | 4375 | 0.490 |
Why?
|
Colony-Stimulating Factors | 1 | 2014 | 221 | 0.490 |
Why?
|
Iliac Artery | 3 | 2016 | 354 | 0.480 |
Why?
|
Potassium Chloride | 6 | 2011 | 247 | 0.470 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 2 | 2016 | 95 | 0.470 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 30 | 0.440 |
Why?
|
Drug-Eluting Stents | 1 | 2018 | 718 | 0.430 |
Why?
|
Venous Pressure | 2 | 2008 | 58 | 0.430 |
Why?
|
Escin | 1 | 2011 | 2 | 0.430 |
Why?
|
Methylenetetrahydrofolate Dehydrogenase (NADP) | 1 | 2011 | 16 | 0.430 |
Why?
|
Calcium Signaling | 3 | 2011 | 754 | 0.430 |
Why?
|
Aneurysm, Infected | 1 | 2012 | 84 | 0.430 |
Why?
|
Aneurysm, Ruptured | 1 | 2016 | 481 | 0.420 |
Why?
|
Cardiovascular Agents | 3 | 2014 | 837 | 0.420 |
Why?
|
Endarterectomy | 1 | 2011 | 202 | 0.410 |
Why?
|
Rats, Sprague-Dawley | 9 | 2020 | 8545 | 0.400 |
Why?
|
Vasodilator Agents | 5 | 2011 | 1002 | 0.400 |
Why?
|
Heart Valve Diseases | 1 | 2018 | 1050 | 0.400 |
Why?
|
Biological Factors | 1 | 2011 | 162 | 0.400 |
Why?
|
Microcirculation | 2 | 2015 | 1294 | 0.400 |
Why?
|
Aortic Diseases | 4 | 2016 | 714 | 0.390 |
Why?
|
Axillary Artery | 2 | 2016 | 42 | 0.380 |
Why?
|
Aneurysm, False | 2 | 2011 | 281 | 0.350 |
Why?
|
Vascular Neoplasms | 1 | 2011 | 179 | 0.350 |
Why?
|
Skin | 4 | 2013 | 4298 | 0.350 |
Why?
|
Angioplasty | 1 | 2011 | 374 | 0.350 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2019 | 11201 | 0.350 |
Why?
|
Tunica Intima | 1 | 2011 | 482 | 0.340 |
Why?
|
Seat Belts | 1 | 2008 | 64 | 0.330 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2008 | 152 | 0.330 |
Why?
|
Femoral Vein | 2 | 2020 | 158 | 0.320 |
Why?
|
Muscle Contraction | 3 | 2020 | 1240 | 0.320 |
Why?
|
Cytokines | 5 | 2016 | 7190 | 0.310 |
Why?
|
Carotid Artery, Internal | 1 | 2010 | 461 | 0.310 |
Why?
|
Blood Vessel Prosthesis | 3 | 2022 | 953 | 0.300 |
Why?
|
Quadriplegia | 1 | 2008 | 186 | 0.300 |
Why?
|
Humans | 82 | 2022 | 715777 | 0.300 |
Why?
|
Angiotensin II | 4 | 2011 | 909 | 0.290 |
Why?
|
Laser Therapy | 1 | 2013 | 1070 | 0.290 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 1 | 2012 | 666 | 0.280 |
Why?
|
Collagenases | 2 | 2016 | 228 | 0.280 |
Why?
|
Metabolomics | 1 | 2014 | 1392 | 0.280 |
Why?
|
Metabolome | 1 | 2012 | 871 | 0.280 |
Why?
|
Osteosarcoma | 1 | 2011 | 890 | 0.270 |
Why?
|
Platelet-Derived Growth Factor | 2 | 2006 | 642 | 0.270 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 723 | 0.270 |
Why?
|
Treatment Outcome | 21 | 2022 | 62004 | 0.260 |
Why?
|
Male | 53 | 2020 | 350324 | 0.260 |
Why?
|
Vertebral Artery Dissection | 1 | 2004 | 48 | 0.250 |
Why?
|
Signal Transduction | 7 | 2019 | 23729 | 0.250 |
Why?
|
Potassium Channels | 1 | 2007 | 569 | 0.250 |
Why?
|
Aorta, Abdominal | 2 | 2004 | 666 | 0.240 |
Why?
|
Inflammation | 3 | 2016 | 10081 | 0.240 |
Why?
|
Carotid Artery Diseases | 1 | 2010 | 890 | 0.240 |
Why?
|
Membrane Potentials | 3 | 2011 | 1167 | 0.240 |
Why?
|
U937 Cells | 2 | 2014 | 275 | 0.240 |
Why?
|
Staphylococcal Infections | 1 | 2012 | 1373 | 0.240 |
Why?
|
Abdominal Abscess | 1 | 2004 | 145 | 0.240 |
Why?
|
Hernia | 1 | 2003 | 66 | 0.240 |
Why?
|
Cell Proliferation | 4 | 2009 | 10620 | 0.230 |
Why?
|
Rats | 8 | 2019 | 24860 | 0.230 |
Why?
|
Cross Infection | 1 | 2012 | 1409 | 0.230 |
Why?
|
Lymphedema | 2 | 2022 | 420 | 0.230 |
Why?
|
Endothelial Cells | 1 | 2016 | 3374 | 0.230 |
Why?
|
Terminology as Topic | 1 | 2010 | 1612 | 0.230 |
Why?
|
Ultrasonography, Doppler, Color | 2 | 2016 | 227 | 0.230 |
Why?
|
Risk Factors | 20 | 2022 | 70866 | 0.230 |
Why?
|
Nitric Oxide Synthase | 3 | 2011 | 938 | 0.220 |
Why?
|
Constriction, Pathologic | 2 | 2018 | 1022 | 0.220 |
Why?
|
Cell Division | 5 | 2004 | 4699 | 0.220 |
Why?
|
Surgical Wound Dehiscence | 1 | 2003 | 214 | 0.220 |
Why?
|
Sclerotherapy | 2 | 2014 | 166 | 0.220 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2012 | 3687 | 0.220 |
Why?
|
Hospital Costs | 1 | 2008 | 976 | 0.220 |
Why?
|
Hernia, Ventral | 1 | 2003 | 136 | 0.210 |
Why?
|
Receptors, Estrogen | 1 | 2010 | 2167 | 0.210 |
Why?
|
Mutation, Missense | 1 | 2011 | 2515 | 0.210 |
Why?
|
Proteomics | 1 | 2014 | 3248 | 0.210 |
Why?
|
Blood Vessels | 1 | 2007 | 1154 | 0.210 |
Why?
|
Baroreflex | 1 | 2022 | 143 | 0.200 |
Why?
|
Lipids | 1 | 2012 | 3242 | 0.200 |
Why?
|
Laparotomy | 1 | 2003 | 469 | 0.200 |
Why?
|
Fluid Shifts | 1 | 2020 | 15 | 0.200 |
Why?
|
Cyclic GMP | 2 | 2011 | 414 | 0.190 |
Why?
|
Animals | 21 | 2020 | 169420 | 0.190 |
Why?
|
Receptors, Adrenergic, alpha | 2 | 2010 | 150 | 0.190 |
Why?
|
Receptor, Angiotensin, Type 1 | 2 | 2011 | 156 | 0.190 |
Why?
|
Popliteal Artery | 1 | 2002 | 308 | 0.190 |
Why?
|
Combined Modality Therapy | 2 | 2011 | 8890 | 0.190 |
Why?
|
Flavonoids | 2 | 2017 | 426 | 0.180 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2002 | 248 | 0.180 |
Why?
|
Fibroblast Growth Factor 2 | 3 | 2008 | 628 | 0.180 |
Why?
|
Down-Regulation | 2 | 2020 | 3066 | 0.180 |
Why?
|
Catheterization, Central Venous | 1 | 2004 | 509 | 0.180 |
Why?
|
Sarcoma | 1 | 2011 | 1878 | 0.180 |
Why?
|
P-Selectin | 1 | 2022 | 616 | 0.180 |
Why?
|
Potassium Channel Blockers | 2 | 2011 | 172 | 0.180 |
Why?
|
Prosthesis-Related Infections | 1 | 2004 | 509 | 0.180 |
Why?
|
Cardiology | 3 | 2022 | 1645 | 0.180 |
Why?
|
Extracellular Fluid | 1 | 2020 | 168 | 0.170 |
Why?
|
Macrophages | 1 | 2014 | 5742 | 0.170 |
Why?
|
Arteriosclerosis | 1 | 2003 | 1131 | 0.170 |
Why?
|
Ischemia | 2 | 2019 | 1906 | 0.170 |
Why?
|
NG-Nitroarginine Methyl Ester | 2 | 2010 | 249 | 0.170 |
Why?
|
Genomics | 1 | 2014 | 5342 | 0.170 |
Why?
|
MAP Kinase Signaling System | 1 | 2006 | 1571 | 0.170 |
Why?
|
Compression Bandages | 2 | 2014 | 15 | 0.160 |
Why?
|
Cyclooxygenase Inhibitors | 2 | 2011 | 391 | 0.160 |
Why?
|
Postthrombotic Syndrome | 2 | 2014 | 30 | 0.160 |
Why?
|
Carotid Arteries | 1 | 2022 | 938 | 0.160 |
Why?
|
Middle Aged | 29 | 2019 | 214639 | 0.150 |
Why?
|
Aged | 27 | 2022 | 162448 | 0.150 |
Why?
|
Aortography | 2 | 2012 | 439 | 0.150 |
Why?
|
Organ Culture Techniques | 1 | 2019 | 856 | 0.150 |
Why?
|
Fatal Outcome | 2 | 2012 | 1879 | 0.150 |
Why?
|
Cell Movement | 2 | 2016 | 5397 | 0.150 |
Why?
|
Hemodynamics | 3 | 2017 | 4214 | 0.150 |
Why?
|
Cytoskeleton | 1 | 2001 | 1219 | 0.140 |
Why?
|
Dilatation, Pathologic | 2 | 2008 | 510 | 0.140 |
Why?
|
Ligation | 1 | 2016 | 480 | 0.140 |
Why?
|
Walking | 2 | 2020 | 1126 | 0.140 |
Why?
|
Female | 35 | 2020 | 377204 | 0.130 |
Why?
|
Veterans Health | 1 | 2016 | 197 | 0.130 |
Why?
|
Ultrasonography, Doppler | 1 | 2017 | 456 | 0.130 |
Why?
|
Inflammation Mediators | 2 | 2014 | 1939 | 0.130 |
Why?
|
Enzyme Inhibitors | 3 | 2011 | 3898 | 0.130 |
Why?
|
Amputation | 1 | 2019 | 763 | 0.130 |
Why?
|
Thrombolytic Therapy | 2 | 2015 | 2158 | 0.120 |
Why?
|
Time Factors | 12 | 2020 | 40875 | 0.120 |
Why?
|
Actins | 1 | 2001 | 2167 | 0.120 |
Why?
|
Predictive Value of Tests | 6 | 2019 | 15199 | 0.120 |
Why?
|
Cell Differentiation | 1 | 2011 | 11655 | 0.120 |
Why?
|
Choice Behavior | 1 | 2019 | 794 | 0.120 |
Why?
|
Spine | 1 | 2020 | 1111 | 0.120 |
Why?
|
Cells, Cultured | 8 | 2008 | 19910 | 0.110 |
Why?
|
Stents | 3 | 2022 | 3207 | 0.110 |
Why?
|
Prostaglandins I | 1 | 2011 | 12 | 0.110 |
Why?
|
Immunohistochemistry | 4 | 2011 | 11689 | 0.110 |
Why?
|
Tuberculosis | 1 | 2004 | 1813 | 0.110 |
Why?
|
Probability | 3 | 2010 | 2487 | 0.110 |
Why?
|
Diosmin | 1 | 2011 | 6 | 0.110 |
Why?
|
Adrenergic alpha-1 Receptor Agonists | 1 | 2011 | 17 | 0.110 |
Why?
|
Patient Preference | 1 | 2019 | 867 | 0.110 |
Why?
|
Receptors, Adrenergic, alpha-1 | 1 | 2011 | 45 | 0.100 |
Why?
|
Isometric Contraction | 2 | 2008 | 151 | 0.100 |
Why?
|
Postoperative Complications | 5 | 2019 | 15079 | 0.100 |
Why?
|
Immunosuppressive Agents | 1 | 2004 | 4194 | 0.100 |
Why?
|
Oxidoreductases, N-Demethylating | 1 | 2011 | 115 | 0.100 |
Why?
|
Tomography, X-Ray Computed | 7 | 2012 | 20356 | 0.100 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2014 | 636 | 0.100 |
Why?
|
Pressoreceptors | 1 | 2010 | 98 | 0.100 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3542 | 0.100 |
Why?
|
Observer Variation | 1 | 2017 | 2676 | 0.100 |
Why?
|
Body Composition | 1 | 2020 | 2395 | 0.100 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 903 | 0.100 |
Why?
|
Meta-Analysis as Topic | 1 | 2015 | 1373 | 0.100 |
Why?
|
Prospective Studies | 9 | 2020 | 51315 | 0.100 |
Why?
|
Prognosis | 5 | 2019 | 29005 | 0.100 |
Why?
|
Evidence-Based Medicine | 4 | 2015 | 3683 | 0.090 |
Why?
|
Receptors, Angiotensin | 1 | 2010 | 139 | 0.090 |
Why?
|
Estrogen Antagonists | 1 | 2010 | 149 | 0.090 |
Why?
|
Transforming Growth Factor beta | 1 | 2017 | 1974 | 0.090 |
Why?
|
Sodium Chloride, Dietary | 1 | 2011 | 256 | 0.090 |
Why?
|
Resistin | 1 | 2010 | 171 | 0.090 |
Why?
|
Apoptosis | 2 | 2008 | 9973 | 0.090 |
Why?
|
Chemokines | 1 | 2014 | 962 | 0.090 |
Why?
|
Estrogen Receptor beta | 1 | 2010 | 172 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 1 | 2011 | 17409 | 0.090 |
Why?
|
Vascular Patency | 1 | 2011 | 841 | 0.090 |
Why?
|
Nitric Oxide Synthase Type III | 2 | 2011 | 712 | 0.090 |
Why?
|
Autopsy | 1 | 2012 | 988 | 0.090 |
Why?
|
Thrombectomy | 2 | 2012 | 681 | 0.080 |
Why?
|
Nitriles | 2 | 2010 | 944 | 0.080 |
Why?
|
Prosthesis Design | 2 | 2022 | 2103 | 0.080 |
Why?
|
Decision Support Techniques | 1 | 2019 | 2032 | 0.080 |
Why?
|
Acetylcholine | 1 | 2010 | 610 | 0.080 |
Why?
|
Wheelchairs | 1 | 2008 | 79 | 0.080 |
Why?
|
Scleroderma, Localized | 1 | 2008 | 77 | 0.080 |
Why?
|
Cromakalim | 1 | 2007 | 16 | 0.080 |
Why?
|
Reference Values | 2 | 2008 | 5050 | 0.080 |
Why?
|
Large-Conductance Calcium-Activated Potassium Channel alpha Subunits | 1 | 2007 | 17 | 0.080 |
Why?
|
Potassium Channels, Calcium-Activated | 1 | 2007 | 48 | 0.080 |
Why?
|
Polytetrafluoroethylene | 1 | 2008 | 235 | 0.080 |
Why?
|
Poisson Distribution | 1 | 2008 | 528 | 0.080 |
Why?
|
Tissue Culture Techniques | 1 | 2008 | 293 | 0.080 |
Why?
|
Adult | 16 | 2020 | 212266 | 0.080 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2010 | 620 | 0.080 |
Why?
|
Hospital Charges | 1 | 2008 | 362 | 0.070 |
Why?
|
Indomethacin | 1 | 2007 | 345 | 0.070 |
Why?
|
Odds Ratio | 5 | 2022 | 9984 | 0.070 |
Why?
|
Biopsy | 2 | 2011 | 6736 | 0.070 |
Why?
|
Hyperemia | 1 | 2007 | 219 | 0.070 |
Why?
|
Caveolin 1 | 1 | 2008 | 258 | 0.070 |
Why?
|
Acute Disease | 3 | 2012 | 7140 | 0.070 |
Why?
|
Phenols | 1 | 2010 | 493 | 0.070 |
Why?
|
Epoprostenol | 1 | 2007 | 279 | 0.070 |
Why?
|
Peripheral Arterial Disease | 1 | 2016 | 1113 | 0.070 |
Why?
|
Lipopolysaccharides | 1 | 2014 | 2244 | 0.070 |
Why?
|
Estrogen Receptor alpha | 1 | 2010 | 579 | 0.070 |
Why?
|
Brachial Artery | 1 | 2007 | 368 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2017 | 21797 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 3947 | 0.070 |
Why?
|
Risk Assessment | 9 | 2019 | 23464 | 0.070 |
Why?
|
Mechanotransduction, Cellular | 1 | 2010 | 522 | 0.070 |
Why?
|
Exudates and Transudates | 1 | 2006 | 179 | 0.070 |
Why?
|
Tuberculosis, Cardiovascular | 1 | 2004 | 9 | 0.070 |
Why?
|
Incidental Findings | 1 | 2010 | 676 | 0.070 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2011 | 1834 | 0.070 |
Why?
|
Logistic Models | 4 | 2016 | 13618 | 0.070 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2013 | 1743 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 374 | 0.070 |
Why?
|
Leukemia | 1 | 2013 | 1514 | 0.070 |
Why?
|
Rifabutin | 1 | 2004 | 53 | 0.070 |
Why?
|
Thigh | 1 | 2006 | 232 | 0.070 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2009 | 653 | 0.070 |
Why?
|
Pressure | 1 | 2008 | 1234 | 0.060 |
Why?
|
Immunoblotting | 1 | 2008 | 1771 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 1 | 2010 | 1137 | 0.060 |
Why?
|
Interleukin-1 | 1 | 2008 | 1265 | 0.060 |
Why?
|
Coronary Restenosis | 1 | 2007 | 425 | 0.060 |
Why?
|
Collagen | 1 | 2013 | 2667 | 0.060 |
Why?
|
Protease Inhibitors | 1 | 2008 | 784 | 0.060 |
Why?
|
Sodium, Dietary | 1 | 2008 | 415 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 3959 | 0.060 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2006 | 346 | 0.060 |
Why?
|
Magnetic Resonance Angiography | 1 | 2011 | 1455 | 0.060 |
Why?
|
Age Factors | 3 | 2017 | 18784 | 0.060 |
Why?
|
Adiponectin | 1 | 2010 | 1089 | 0.060 |
Why?
|
Random Allocation | 1 | 2008 | 2445 | 0.060 |
Why?
|
Takayasu Arteritis | 1 | 2004 | 92 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1267 | 0.060 |
Why?
|
Receptors, Growth Factor | 1 | 2004 | 342 | 0.060 |
Why?
|
Aortic Aneurysm | 1 | 2008 | 663 | 0.060 |
Why?
|
Isoniazid | 1 | 2004 | 260 | 0.060 |
Why?
|
Severity of Illness Index | 4 | 2011 | 15909 | 0.060 |
Why?
|
Vascular Fistula | 1 | 2003 | 50 | 0.060 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 641 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2010 | 1334 | 0.060 |
Why?
|
Jugular Veins | 1 | 2004 | 213 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2019 | 9596 | 0.060 |
Why?
|
Estrogens | 1 | 2010 | 1529 | 0.060 |
Why?
|
Societies, Medical | 2 | 2014 | 3754 | 0.060 |
Why?
|
Oligopeptides | 1 | 2008 | 1236 | 0.060 |
Why?
|
Duodenal Diseases | 1 | 2003 | 100 | 0.060 |
Why?
|
Hypertension | 3 | 2017 | 8270 | 0.060 |
Why?
|
Polyethylene Terephthalates | 1 | 2002 | 108 | 0.060 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2010 | 1203 | 0.060 |
Why?
|
Retinoblastoma Protein | 1 | 2006 | 698 | 0.060 |
Why?
|
Estradiol | 1 | 2010 | 1978 | 0.060 |
Why?
|
Tibial Arteries | 1 | 2002 | 56 | 0.060 |
Why?
|
Up-Regulation | 2 | 2010 | 4312 | 0.060 |
Why?
|
Prosthesis Failure | 1 | 2008 | 1211 | 0.060 |
Why?
|
Intestinal Fistula | 1 | 2003 | 150 | 0.050 |
Why?
|
Pulmonary Embolism | 1 | 2015 | 2360 | 0.050 |
Why?
|
Debridement | 1 | 2004 | 497 | 0.050 |
Why?
|
Sensitivity and Specificity | 3 | 2010 | 14902 | 0.050 |
Why?
|
Fibrinolytic Agents | 1 | 2012 | 2124 | 0.050 |
Why?
|
Endoleak | 1 | 2022 | 97 | 0.050 |
Why?
|
Imidazoles | 1 | 2008 | 1250 | 0.050 |
Why?
|
Extracellular Matrix | 1 | 2009 | 1755 | 0.050 |
Why?
|
Retrospective Studies | 7 | 2022 | 72443 | 0.050 |
Why?
|
Regional Blood Flow | 2 | 2019 | 1558 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 2 | 2008 | 5412 | 0.050 |
Why?
|
Radiography | 1 | 2011 | 6978 | 0.050 |
Why?
|
Aged, 80 and over | 7 | 2019 | 58323 | 0.050 |
Why?
|
Disease Progression | 2 | 2012 | 13215 | 0.050 |
Why?
|
Quality Improvement | 1 | 2015 | 3738 | 0.050 |
Why?
|
Length of Stay | 2 | 2016 | 6267 | 0.050 |
Why?
|
Fibronectins | 2 | 2003 | 720 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3494 | 0.050 |
Why?
|
Neovascularization, Physiologic | 1 | 2007 | 1403 | 0.050 |
Why?
|
Pyrazoles | 1 | 2010 | 1957 | 0.050 |
Why?
|
Administration, Topical | 1 | 2021 | 701 | 0.050 |
Why?
|
Phosphorylation | 2 | 2008 | 8658 | 0.050 |
Why?
|
Health Care Costs | 1 | 2013 | 3164 | 0.050 |
Why?
|
Patient Selection | 3 | 2022 | 4293 | 0.050 |
Why?
|
Expert Testimony | 1 | 2022 | 358 | 0.050 |
Why?
|
Delphi Technique | 1 | 2022 | 727 | 0.040 |
Why?
|
Extracellular Space | 1 | 2001 | 606 | 0.040 |
Why?
|
Propensity Score | 2 | 2016 | 1759 | 0.040 |
Why?
|
Device Removal | 1 | 2004 | 648 | 0.040 |
Why?
|
Drainage | 1 | 2004 | 1132 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 1999 | 385 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2014 | 13217 | 0.040 |
Why?
|
Pre-Eclampsia | 1 | 2007 | 1108 | 0.040 |
Why?
|
Physicians | 1 | 2016 | 4375 | 0.040 |
Why?
|
beta-Galactosidase | 1 | 1999 | 611 | 0.040 |
Why?
|
Information Seeking Behavior | 1 | 2019 | 128 | 0.040 |
Why?
|
Linear Models | 1 | 2008 | 5983 | 0.040 |
Why?
|
Dyslipidemias | 1 | 2005 | 847 | 0.040 |
Why?
|
Streptonigrin | 1 | 1997 | 1 | 0.040 |
Why?
|
Blood Pressure | 2 | 2011 | 8544 | 0.040 |
Why?
|
Blotting, Western | 3 | 2011 | 5379 | 0.040 |
Why?
|
Pericardium | 1 | 2002 | 660 | 0.040 |
Why?
|
Bioprosthesis | 1 | 2002 | 612 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 14911 | 0.040 |
Why?
|
Breast Neoplasms, Male | 1 | 1999 | 201 | 0.040 |
Why?
|
Blood Loss, Surgical | 2 | 2016 | 661 | 0.040 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4455 | 0.040 |
Why?
|
Antitubercular Agents | 1 | 2004 | 1294 | 0.040 |
Why?
|
Electric Impedance | 1 | 2020 | 652 | 0.040 |
Why?
|
Pyridines | 1 | 2008 | 2846 | 0.040 |
Why?
|
Palliative Care | 1 | 2011 | 3286 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12480 | 0.040 |
Why?
|
Biopsy, Needle | 1 | 2001 | 1673 | 0.030 |
Why?
|
Sex Factors | 1 | 2010 | 10666 | 0.030 |
Why?
|
Cell Death | 1 | 2001 | 1724 | 0.030 |
Why?
|
United States | 6 | 2022 | 67905 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2950 | 0.030 |
Why?
|
Permeability | 1 | 2017 | 786 | 0.030 |
Why?
|
Peptides | 1 | 2007 | 4384 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2019 | 1525 | 0.030 |
Why?
|
Capillaries | 1 | 2017 | 777 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7095 | 0.030 |
Why?
|
Mycobacterium tuberculosis | 1 | 2004 | 1811 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39300 | 0.030 |
Why?
|
Cross-Over Studies | 1 | 2019 | 2015 | 0.030 |
Why?
|
Diagnostic Techniques, Cardiovascular | 1 | 2014 | 157 | 0.030 |
Why?
|
Antibiotics, Antineoplastic | 1 | 1997 | 675 | 0.030 |
Why?
|
Young Adult | 2 | 2017 | 56226 | 0.030 |
Why?
|
Edema | 1 | 2017 | 769 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 2743 | 0.030 |
Why?
|
Disease Models, Animal | 2 | 2011 | 18199 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 2005 | 2548 | 0.030 |
Why?
|
Protein Isoforms | 1 | 2017 | 1695 | 0.030 |
Why?
|
Pneumonia | 1 | 2004 | 2099 | 0.030 |
Why?
|
Atherosclerosis | 1 | 2007 | 3159 | 0.030 |
Why?
|
United States Department of Veterans Affairs | 1 | 2016 | 857 | 0.030 |
Why?
|
Echinomycin | 1 | 2010 | 2 | 0.030 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 4893 | 0.030 |
Why?
|
Stress, Mechanical | 1 | 2016 | 1685 | 0.030 |
Why?
|
Butadienes | 1 | 2010 | 117 | 0.030 |
Why?
|
Cell Cycle | 1 | 1999 | 2993 | 0.030 |
Why?
|
Guanylate Cyclase | 1 | 2011 | 211 | 0.020 |
Why?
|
Databases, Factual | 2 | 2016 | 7895 | 0.020 |
Why?
|
Benzoquinones | 1 | 2010 | 207 | 0.020 |
Why?
|
Analysis of Variance | 1 | 1999 | 6501 | 0.020 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 2998 | 0.020 |
Why?
|
Renin | 1 | 2011 | 618 | 0.020 |
Why?
|
Thrombosis | 1 | 2003 | 2843 | 0.020 |
Why?
|
Lactams, Macrocyclic | 1 | 2010 | 322 | 0.020 |
Why?
|
Histone Demethylases | 1 | 2011 | 297 | 0.020 |
Why?
|
Smoking | 1 | 2005 | 8980 | 0.020 |
Why?
|
Self Report | 1 | 2019 | 3416 | 0.020 |
Why?
|
Muscle Relaxation | 1 | 2008 | 143 | 0.020 |
Why?
|
Adipokines | 1 | 2010 | 310 | 0.020 |
Why?
|
Molecular Weight | 1 | 2010 | 2413 | 0.020 |
Why?
|
Aldosterone | 1 | 2011 | 819 | 0.020 |
Why?
|
Program Evaluation | 1 | 2015 | 2539 | 0.020 |
Why?
|
Algorithms | 2 | 2005 | 13758 | 0.020 |
Why?
|
Cyclin D | 1 | 2006 | 68 | 0.020 |
Why?
|
Reoperation | 1 | 2016 | 4169 | 0.020 |
Why?
|
Pregnancy | 1 | 2007 | 27398 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2010 | 12539 | 0.020 |
Why?
|
Aorta, Thoracic | 1 | 2011 | 1029 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2010 | 2069 | 0.020 |
Why?
|
Angiography | 1 | 2010 | 1625 | 0.020 |
Why?
|
Models, Statistical | 1 | 2019 | 5064 | 0.020 |
Why?
|
Aging | 1 | 2003 | 8350 | 0.020 |
Why?
|
Mice, Knockout | 2 | 2011 | 15059 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 2993 | 0.020 |
Why?
|
Cyclins | 1 | 2006 | 598 | 0.020 |
Why?
|
Proportional Hazards Models | 2 | 2010 | 12456 | 0.020 |
Why?
|
RNA, Messenger | 2 | 2010 | 13213 | 0.020 |
Why?
|
Hematemesis | 1 | 2003 | 25 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2007 | 1438 | 0.010 |
Why?
|
Patient Discharge | 1 | 2016 | 3030 | 0.010 |
Why?
|
Cell Line | 1 | 2017 | 16576 | 0.010 |
Why?
|
Cardiovascular Diseases | 1 | 2007 | 14438 | 0.010 |
Why?
|
Hospital Mortality | 1 | 2016 | 5132 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2001 | 24798 | 0.010 |
Why?
|
Comorbidity | 1 | 2016 | 10435 | 0.010 |
Why?
|
Surgical Mesh | 1 | 2002 | 249 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2020 | 23438 | 0.010 |
Why?
|
Graft Survival | 1 | 2010 | 3750 | 0.010 |
Why?
|
Recurrence | 1 | 2011 | 8240 | 0.010 |
Why?
|
Anastomosis, Surgical | 1 | 2002 | 948 | 0.010 |
Why?
|
Electron Spin Resonance Spectroscopy | 1 | 1997 | 170 | 0.010 |
Why?
|
Methanol | 1 | 1997 | 90 | 0.010 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2003 | 624 | 0.010 |
Why?
|
Drug Stability | 1 | 1997 | 304 | 0.010 |
Why?
|
Body Weight | 1 | 2008 | 4688 | 0.010 |
Why?
|
Genotype | 1 | 2011 | 12919 | 0.010 |
Why?
|
Solutions | 1 | 1997 | 412 | 0.010 |
Why?
|
Dimethyl Sulfoxide | 1 | 1997 | 253 | 0.010 |
Why?
|
Kaplan-Meier Estimate | 1 | 2007 | 6722 | 0.010 |
Why?
|
Solvents | 1 | 1997 | 295 | 0.010 |
Why?
|
Quality of Life | 1 | 2017 | 11721 | 0.010 |
Why?
|
Ultrasonography | 1 | 2007 | 5922 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2010 | 13643 | 0.010 |
Why?
|
Phenotype | 1 | 2011 | 16311 | 0.010 |
Why?
|
Mice | 2 | 2011 | 80375 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 1997 | 2599 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1997 | 3206 | 0.010 |
Why?
|
Temperature | 1 | 1997 | 2145 | 0.010 |
Why?
|
Diet | 1 | 2008 | 7565 | 0.010 |
Why?
|
Indoles | 1 | 1997 | 1845 | 0.010 |
Why?
|
Incidence | 1 | 1999 | 20731 | 0.000 |
Why?
|